JP Morgan Chase
MRTX

JP Morgan Chase’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

JP Morgan Chase’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-108,407
Closed -$6.37M – 8092
2023
Q4 		$6.37M Buy
108,407
+38,528
+55% +$2.17M ﹤0.01% 2877
2023
Q3 		$3.04M Buy
69,879
+30,805
+79% +$1.1M ﹤0.01% 3215
2023
Q2 		$1.41M Sell
39,074
-20,774
-35% -$856K ﹤0.01% 3801
2023
Q1 		$2.23M Buy
59,848
+16,842
+39% +$758K ﹤0.01% 3470
2022
Q4 		$1.95M Sell
43,006
-116,870
-73% -$7.56M ﹤0.01% 3577
2022
Q3 		$11.2M Buy
159,876
+105,147
+192% +$7.78M ﹤0.01% 2064
2022
Q2 		$3.67M Buy
54,729
+26,463
+94% +$1.68M ﹤0.01% 3050
2022
Q1 		$2.32M Buy
28,266
+2,164
+8% +$221K ﹤0.01% 3635
2021
Q4 		$3.83M Buy
26,102
+3,259
+14% +$506K ﹤0.01% 3282
2021
Q3 		$4.04M Sell
22,843
-2,747
-11% -$442K ﹤0.01% 3212
2021
Q2 		$4.13M Sell
25,590
-305,484
-92% -$49M ﹤0.01% 3224
2021
Q1 		$56.7M Sell
331,074
-28,315
-8% -$5.61M 0.01% 1105
2020
Q4 		$78.9M Buy
359,389
+84,745
+31% +$18.3M 0.01% 871
2020
Q3 		$45.6M Buy
274,644
+258,420
+1,593% +$35.4M 0.01% 1019
2020
Q2 		$1.85M Buy
16,224
+5,522
+52% +$536K ﹤0.01% 3157
2020
Q1 		$824K Sell
10,702
-6,510
-38% -$584K ﹤0.01% 3533
2019
Q4 		$2.22M Buy
17,212
+6,931
+67% +$669K ﹤0.01% 3317
2019
Q3 		$801K Buy
10,281
+1,951
+23% +$183K ﹤0.01% 3955
2019
Q2 		$871K Buy
8,330
+449
+6% +$35K ﹤0.01% 3945
2019
Q1 		$577K Buy
7,881
+2,729
+53% +$186K ﹤0.01% 4131
2018
Q4 		$219K Buy
5,152
+480
+10% +$19.1K ﹤0.01% 4558
2018
Q3 		$220K Buy
4,672
+994
+27% +$55.3K ﹤0.01% 4658
2018
Q2 		$181K Buy
+3,678
New +$139K ﹤0.01% 4602
2017
Q4 		– Sell
-2,777
Closed -$32K – 5623
2017
Q3 		$32K Buy
+2,777
New +$16.1K ﹤0.01% 4558
2017
Q2 		– Sell
-37,366
Closed -$194K – 5293
2017
Q1 		$194K Sell
37,366
-16,895
-31% -$92.6K ﹤0.01% 4082
2016
Q4 		$258K Buy
54,261
+24,201
+81% +$132K ﹤0.01% 4062
2016
Q3 		$199K Sell
30,060
-26,350
-47% -$140K ﹤0.01% 3689
2016
Q2 		$308K Sell
56,410
-20,750
-27% -$331K ﹤0.01% 3595
2016
Q1 		$1.65M Buy
77,160
+4,135
+6% +$92.5K ﹤0.01% 2801
2015
Q4 		$2.31M Sell
73,025
-8,500
-10% -$300K ﹤0.01% 2683
2015
Q3 		$2.81M Buy
81,525
+2,125
+3% +$64.2K ﹤0.01% 2580
2015
Q2 		$2.5M Sell
79,400
-5,925
-7% -$175K ﹤0.01% 2779
2015
Q1 		$2.5M Sell
85,325
-3,475
-4% -$81.5K ﹤0.01% 2761
2014
Q4 		$1.65M Sell
88,800
-4,325
-5% -$72.9K ﹤0.01% 3075
2014
Q3 		$1.63M Buy
+93,125
New +$1.74M ﹤0.01% 3058

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's MRTX Position: Q1 2024 in Review

JP Morgan Chase sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 108,407 shares — an estimated $6.37M sold.

JP Morgan Chase first reported a position in MRTX in Q3 2014 and held it in 35 quarters. The position peaked at $78.9M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • JP Morgan Chase reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • JP Morgan Chase sold 108,407 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $6.37M.
  • JP Morgan Chase first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2014 and held it in 35 quarters.
  • JP Morgan Chase's Mirati Therapeutics, Inc. Common Stock position peaked at $78.9M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.